TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from enGene Holdings ( (ENGN) ) is now available.
On November 12, 2025, enGene Holdings Inc. announced the pricing of its public offering of 12,558,823 common shares and pre-funded warrants, expected to raise approximately $130 million. The offering closed on November 14, 2025, and is anticipated to enhance enGene’s financial position, potentially impacting its market presence and stakeholder interests.
The most recent analyst rating on (ENGN) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on enGene Holdings stock, see the ENGN Stock Forecast page.
Spark’s Take on ENGN Stock
According to Spark, TipRanks’ AI Analyst, ENGN is a Neutral.
enGene Holdings shows significant financial challenges, with no revenue generation and persistent losses impacting both income and cash flow statements. Technical indicators suggest bearish momentum, with the stock underperforming key moving averages. The valuation is further hampered by a negative P/E ratio and absence of dividends. These factors collectively result in a low overall stock score, highlighting the company’s urgent need to establish a revenue model and improve operational efficiency.
To see Spark’s full report on ENGN stock, click here.
More about enGene Holdings
enGene Holdings Inc. is a clinical-stage biotechnology company that focuses on genetic medicine, delivering therapeutics to mucosal tissues and other organs. Its lead program, detalimogene voraplasmid, targets non-muscle invasive bladder cancer and is being evaluated in a Phase 2 trial.
Average Trading Volume: 1,151,493
Technical Sentiment Signal: Buy
Current Market Cap: $444.3M
For an in-depth examination of ENGN stock, go to TipRanks’ Overview page.